Barrett’s esophagus is one of the major complications of gastro-esophageal reflux disease (GERD) in which the normal squamous tissue lining the esophagus changes to the tissue resembling that of the intestine lining. This disease is caused by the damage to the esophagus from the chronic backwash of stomach contents (like enzymes and acid) that occurs with abnormal reflux.

 

DelveInsight’s “Barett Esophagus Market Insights, Epidemiology, and Market Forecast-2030″ report delivers an in-depth understanding of the Barett Esophagus, historical and forecasted epidemiology as well as the Barett Esophagus market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

Some facts of Barett Esophagus Market Report are:

• Barrett’s esophagus is considered to be the primary risk factor for esophageal cancer.
• Over 10% of individuals with GERD develop Barrett’s esophagus.
• Over 12 million adults in the Americas are anticipated to be suffering from Barrett’s esophagus, of which over 1.5 million have only been diagnosed.
• It has been estimated that around 1.6% to 6.8% of total global population suffers from the disease every year till date and this share is expected to increase during the forecast period.
• It is estimated that over 0.5% of the patients with Barrett’s esophagus develop esophageal cancer.

 

Request for Sample Report: https://www.delveinsight.com/sample-request/barett-esophagus-market

 

Scope of Barett Esophagus Market Report are:

• The report covers the descriptive overview of Barett Esophagus, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
• Comprehensive insight has been provided into the Barett Esophagus epidemiology and treatment in the 7MM
• Additionally, an all-inclusive account of both the current and emerging therapies for Barett Esophagus are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
• A detailed review of Barett Esophagus market; historical and forecasted is included in the report, covering drug outreach in the 7MM
• The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Barett Esophagus market

 

Request for Sample Report: https://www.delveinsight.com/sample-request/barett-esophagus-market

 

The intestinal cells in Barrett’s esophagus are more resistant to stomach acid than squamous cells, indicating that the tissue changes that occur are to protect the esophagus from acid exposure. This disease is commonly observed in men than in women, and is more common in white population as compared to Hispanic population, and is rare in Asian and black population. Barrett’s esophagus does not present any symptoms, and the patients’ seek treatment for GERD symptoms.

 

Some of Barett Esophagus Companies are:

• Addex Therapeutics
• AstraZeneca, Plc
• Rottapharm (Meda AB)
• Takeda
• Eisai Co. Ltd.
• Pfizer, Inc.
• Torax Medical
• Mederi Therapeutics
• Aros Pharma
• Torax Medical
• C. R. Bard
• And Many Others

 

 

Barett Esophagus Market Report Highlights

• In the coming years, Barett Esophagus market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
• The companies and academics are working to assess challenges and seek opportunities that could influence Barett Esophagus R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition     
• Major players are involved in developing therapies for Barett Esophagus. Launch of emerging therapies will significantly impact the Barett Esophagus market
• A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Barett Esophagus
• Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

 

Table of Contents:

1. Key Insights

2. Executive Summary of Barett Esophagus

3. Competitive Intelligence Analysis for Barett Esophagus

4. Barett Esophagus: Market Overview at a Glance

5. Barett Esophagus: Disease Background and Overview

6. Patient Journey

7. Barett Esophagus Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

8.1. Barett Esophagus Treatment and Management

8.2. Barett Esophagus Treatment Algorithm

9. Unmet Needs

10. Key Endpoints of Barett Esophagus Treatment

11. Marketed Products

List to be continued in report

12. Emerging Therapies

List to be continued in report

13. Barett Esophagus: Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of Barett Esophagus

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

20.1. Bibliography

20.2. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

 

About DelveInsight

DelveInsight is a premier Business Consulting and Market Research firm focused exclusively on the life science segment. With a wide array of smart end-to-end solutions, the firm helps the global Pharmaceutical and Bio-Tech companies formulate prudent business decisions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/report-store/barett-esophagus-market